A Phase I Study of Neoadjuvant Capecitabine, Oxaliplatin, and Irinotecan (XELOXIRI) in Patients with Locally Advanced Rectal Cancer.

CONCLUSIONS: XELOXIRI is a feasible and active regimen for patients with locally advanced rectal cancer. Febrile neutropenia was the DLT, and the RD of irinotecan is 150 mg/m2.
PMID: 31266024 [PubMed - as supplied by publisher]

Source: Oncology - July 1, 2019 Category: Cancer & Oncology Authors: Kudo T, Takemasa I, Hata T, Sakai D, Takahashi H, Haraguchi N, Nishimura J, Hata T, Matsuda C, Satoh T, Mizushima T, Mori M, Doki Y Tags: Oncology Source Type: research